EHang Holdings Ltd - ADR (EH) Stock Price Today
Aura AI Summary
Key Stats
- $423.98MMarket Cap
- -Volume
- IndustrialsSector
- $19.4452W High
- $4.9052W Low
- -Typical Hold Time
- $363.64MEnterprise Value
- -Div Yield
- -Trading Activity
Track EHang Holdings Ltd - ADR (EH) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, EHang Holdings Ltd - ADR has traded between a low of $4.9 and a high of $19.44, highlighting its annual price range. Buy and sell EHang Holdings Ltd - ADR shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Most Recent News
Berkshire's new CEO cuts Chevron stake, adds virtual monopoly as top 5 holding.
Greg Abel, Warren Buffett's successor as CEO of Berkshire Hathaway, began his leadership by significantly reducing the company's investment in Chevron. At the same time, he introduced a virtual monopoly company into Berkshire's top five holdings, sig...
Jingxing HK and Cainiao Group partner to expand smart warehousing in Europe, starting with Spain and Netherlands projects.
Jingxing Storage Equipment Engineering (H.K.) Company Limited, a subsidiary of Reitar Logtech, has signed a Global Strategic Cooperation Agreement with Cainiao Group to jointly develop and deploy smart warehousing and automated logistics solutions wo...
Vaximm to publish promising clinical data on VXM01 cancer vaccine for glioblastoma.
Vaximm AG, a subsidiary of OSR Health, announced it will publish clinical data from two studies on VXM01, an oral DNA vaccine targeting VEGFR-2, in recurrent glioblastoma patients. The vaccine showed safety, immune activation, and dose-dependent effe...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.